Navigation Links
Quest Diagnostics to Speak at the Lazard Capital Markets 8th Annual Healthcare Conference
Date:11/11/2011

MADISON, N.J., Nov. 11, 2011 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Lazard Capital Markets 8th Annual Healthcare Conference in New York City.  The presentation is scheduled for Tuesday, November 15, 2011 at 11:30 a.m. Eastern Time.

During the conference, the company will reaffirm its 2011 outlook before future special items. The company expects revenues to grow 1.5% and, on an adjusted basis, operating income as a percentage of revenues to be 17.5% and earnings per share to be between $4.30 and $4.35. The outlook on an adjusted basis excludes the impact of the Medi-Cal charge, restructuring charges, costs associated with the Athena and Celera transactions, and the estimated impact of severe weather in the first quarter of 2011.

The presentation will be webcast live during the conference and will be available to registered investors on the following site: http://wsw.com/webcast/lz11/dgx/ and to the public on www.QuestDiagnostics.com/investor.  In addition, the archived webcast will be available one hour after the conclusion of the live event and will remain available until December 15, 2011.  

Quest Diagnostics Incorporated (NYSE: DGX) is the world's leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is
'/>"/>

SOURCE Quest Diagnostics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children
2. VioQuest Pharmaceuticals Completes Enrollment of Phase I Trial of Lenocta(TM)
3. Two Point of Care Tests From Quest Diagnostics Receive FDA 510(k) Clearance
4. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
5. VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor
6. Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis
7. U.S. Patent Office Rejects Key HIV/AIDS Drug Patents at PUBPAT Request: Government Finds Prior Art Submitted By PUBPAT Invalidates All of Gilead Sciences Claims
8. Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes
9. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
10. BRAVE-3 Questions Value of Abciximab in PCI for Heart Attack
11. ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Fla. , Jan. 23, 2015  HyGreen, Inc., a ... agreement and partnership with RCA Medical, a subsidiary of ... . Each year, hundreds of millions ... care-associated infections as organisms are transmitted from patient to ...
(Date:1/23/2015)... Africa , Jan. 23, 2015   Leatt Corporation ... personal protective equipment for all forms of sports, including ... Leatt-Brace® neck brace, announced today that the UISP Lega ... now requires all riders to wear a neck brace ...
(Date:1/23/2015)... China , Jan. 23, 2015 Tianyin Pharmaceutical ... company that specializes in the development and sale of ... generics and active pharmaceutical ingredients (API) today announced the ... (JCM) API operation. 1. Following the September ...
Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4
... 19, 2007 - Abraxis BioScience,Inc. (NASDAQ:ABBI), ... from two pre-clinical studies that,provide evidence ... combining nab-paclitaxel (ABRAXANE(R) for Injectable,Suspension (paclitaxel ... VEGF inhibitor drugs like,bevacizumab (Avastin(R)) at ...
... WIRE)--Apr 19, 2007 - Abraxis BioScience,Inc. ... first-time data from a pre-clinical study,evaluating ... nab-rapamycin,(ABI-009), an albumin-bound mTOR kinase inhibitor, ... Research (AACR) Annual Meeting held,April 14-18, ...
Cached Medicine Technology:Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 2Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 3Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 4Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response 5Abraxis BioScience Presents Results from Pre-Clinical Study That,Demonstrates nab-Rapamycin's Robust Antitumor Properties and,Ability to Target Intracellular Sites Such as the mTOR Pathway 2Abraxis BioScience Presents Results from Pre-Clinical Study That,Demonstrates nab-Rapamycin's Robust Antitumor Properties and,Ability to Target Intracellular Sites Such as the mTOR Pathway 3Abraxis BioScience Presents Results from Pre-Clinical Study That,Demonstrates nab-Rapamycin's Robust Antitumor Properties and,Ability to Target Intracellular Sites Such as the mTOR Pathway 4
(Date:1/22/2015)... Payday lending practices in four southern states ... distress to the states that permit them, according to ... on Race and Wealth. , While they generate hundreds ... at the same time substantially depress economic activity, according ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 As interest in ... health care gains momentum worldwide, Rev. Eric J. Hall ... Chaplaincy Network (HCCN), will be the keynote speaker on ... in Israel’s public health system. , The conference, “Hope and ...
(Date:1/22/2015)... Compare-autoinsurance.org has released a new blog post presenting a list ... policy . , Some types of vehicles cannot be covered ... released blog post to see if their vehicle qualifies for auto ... some of the cars that cannot be covered by a plan. ...
(Date:1/22/2015)... January 22, 2015 Step into a ... the Science Museum of Virginia. Wicked Plants, the Museum’s ... Plants unearths 75 poisonous, carnivorous and diabolical plants inside ... room to uncover the biochemical, physical and neurological processes ...
(Date:12/26/2014)... The US represents the largest market for CRC across the ... that sales of branded therapies were $2.23 billion. The US ... of the disease, high drug treatment rate, and higher drug ... of CRC therapies over the forecast period will be driven ...
Breaking Medicine News(10 mins):Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:Wicked Plants are taking over the Science Museum of Virginia 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4
... 2 copies of variant, puffing before age 17 boosted odds ... -- People with certain common genetic variations that affect their ... life-long nicotine addicts if they begin smoking before they turn ... people who begin smoking at a young age are more ...
... NEW YORK, July 17 Fresh Harvest Products,Inc. ... is expanding and,enhancing its long standing commitment to ... offerings, through a new initiative to,build natural and ... side the Fresh Harvest brands,through our network., ...
... A NEW SOUTH AFRICA TO PRODUCE, HACHETTE AUDIO TO ... PROGRAMS SERVING AFRICAN AIDS ORPHANS, LOS ANGELES, July ... week, Artists for a New South Africa (ANSA) announced ... African,Folktales, an award-winning book of legendary tales hand-picked by ...
... Uninsured Fail to Address the High Percentage of people with Mental ... ... July 17, 2008 -- New data indicates that more than one ... or addiction disorder, or both., , , , ,Many state healthcare ...
... France, July 17 - First-Half 2008 Revenue ... Constant Exchange Rates Essilor International, the ... EUR1,520.3 million for the six months,ended June 30, 2008, ... Like-for-like growth was 5.4%, in line with trend rates, ...
... a privately held medical device manufacturer focusing on ... today announced that the company has closed a ... leading venture capital firms active in medical technology. ... Foundation Medical Partners and were joined in the ...
Cached Medicine News:Health News:Gene Mutation Puts Some Kids at Risk for Tobacco Addiction 2Health News:Fresh Harvest Products, Inc. Announces New Brand Initiative 2Health News:Nelson Mandela's Favorite African Folktales to be Produced as Audiobook Featuring Archbishop Tutu, Gillian Anderson, America Ferrera, Whoopi Goldberg, Samuel L. Jackson, Alan Rickman and Jurnee Smollett, Directed by Alfre Woodard 2Health News:Nelson Mandela's Favorite African Folktales to be Produced as Audiobook Featuring Archbishop Tutu, Gillian Anderson, America Ferrera, Whoopi Goldberg, Samuel L. Jackson, Alan Rickman and Jurnee Smollett, Directed by Alfre Woodard 3Health News:Uninsured With Mental Illness and Addiction Disorders Not Covered by State Healthcare Initiatives 2Health News:Essilor - First-Half 2008 Revenue 2Health News:Essilor - First-Half 2008 Revenue 3Health News:Essilor - First-Half 2008 Revenue 4Health News:Essilor - First-Half 2008 Revenue 5Health News:Vertos Medical Inc. Completes Series C Financing 2Health News:Vertos Medical Inc. Completes Series C Financing 3Health News:Vertos Medical Inc. Completes Series C Financing 4
For monitoring vacuum pressure, suitable for use with all QIAvac manifolds;...
... Millex Filter Units,Filter units with ... hydrophobic Fluoropore membrane are ideal for ... venting of sterile containers, and for ... sterile 25 mm Millex filter units ...
... Undercounter refrigerator -4C. ... is reversible. Interior light. ... Two see-through drawers. Two ... large bottles. Adjustable thermostat. ...
Designed to meet the requirements of reagent grade water for routine analysis....
Medicine Products: